Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review

Kiyoe Kurahashi; Itsuro Endo; Takeshi Kondo; Kana Morimoto; Sumiko Yoshida; Akio Kuroda; Ken-ichi Aihara; Munehide Matsuhisa; Kohei Nakajima; Yoshifumi Mizobuchi; Shinji Nagahiro; Masahiro Abe; Seiji Fukumoto

doi:10.2169/internalmedicine.8223-16

CASE REPORTS

Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review

Kiyoe Kurahashi, Itsuro Endo, Takeshi Kondo, Kana Morimoto, Sumiko Yoshida, Akio Kuroda, Ken-ichi Aihara, Munehide Matsuhisa, Kohei Nakajima, Yoshifumi Mizobuchi, Shinji Nagahiro, Masahiro Abe, Seiji Fukumoto

Author information

Kiyoe Kurahashi
Department of Hematology, Endocrinology & Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan
Itsuro Endo
Department of Hematology, Endocrinology & Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan
Takeshi Kondo
Department of Hematology, Endocrinology & Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan
Kana Morimoto
Department of Hematology, Endocrinology & Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan
Sumiko Yoshida
Department of Hematology, Endocrinology & Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan
Akio Kuroda
Diabetes Therapeutics and Research Center, Tokushima University, Japan
Ken-ichi Aihara
Department of Hematology, Endocrinology & Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan
Munehide Matsuhisa
Diabetes Therapeutics and Research Center, Tokushima University, Japan
Kohei Nakajima
Department of Neurosurgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
Yoshifumi Mizobuchi
Department of Neurosurgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
Shinji Nagahiro
Department of Neurosurgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
Masahiro Abe
Department of Hematology, Endocrinology & Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan
Seiji Fukumoto
Institute of Advanced Medical Sciences, Fujii Memorial Institute of Medical Sciences, Tokushima University, Japan

Keywords: GH-secreting macroadenoma, somatostatin analogue, remarkable shrinkage

JOURNAL OPEN ACCESS

2017 Volume 56 Issue 18 Pages 2455-2461

DOI https://doi.org/10.2169/internalmedicine.8223-16

Browse “Advance online publication” version

Details

Abstract

Acromegaly is caused by excessive growth hormone secretion, usually from pituitary adenomas. Somoatostatin analogues are widely used as primary or adjunctive therapy in the management of acromegaly. In this report, we present a case with remarkable shrinkage of a tumor after relatively short-term octreotide long-acting release (LAR) administration. During the 30-month follow-up after starting octreotide LAR, there was no recurrence of acromegaly with remarkable shrinkage of the tumor on pituitary magnetic resonance imaging. A literature review of the predictors for tumor shrinkage after the administration of somatostatin analogues in patients with acromegaly is also discussed in relation to this case.

Corresponding author

Register with J-STAGE for free!